Clinical Trial: MT2022-01: MSCs for ALD
Study Status: Completed
Recruit Status: RECRUITING
Condition: Cerebral Adrenoleukodystrophy
Study Type: INTERVENTIONAL
Official Title: Intravenous Administration of Mesenchymal Stem Cells (IV-MSC) for the Treatment of Cerebral Adrenoleukodystrophy (cALD)
Brief Summary:
This is a single-institution study to evaluate the use of intravenously administered allogeneic, 3rd party mesenchymal stem cells (IV-MSC) in patients with active, cerebral adrenoleukodystrophy (CALD), as a bridge to hematopoietic stem cell transplant or gene therapy, or in patients who are too advanced for gene therapy or HSCT.The intervention will occur in the time between diagnosis of active CALD and transplant which is currently 8-12 weeks.
Read more